ZA200200177B - Indole derivatives and their use for the treatment of osteoporosis amongst other applications. - Google Patents

Indole derivatives and their use for the treatment of osteoporosis amongst other applications. Download PDF

Info

Publication number
ZA200200177B
ZA200200177B ZA200200177A ZA200200177A ZA200200177B ZA 200200177 B ZA200200177 B ZA 200200177B ZA 200200177 A ZA200200177 A ZA 200200177A ZA 200200177 A ZA200200177 A ZA 200200177A ZA 200200177 B ZA200200177 B ZA 200200177B
Authority
ZA
South Africa
Prior art keywords
formula
compound
pharmaceutically acceptable
indol
dichloro
Prior art date
Application number
ZA200200177A
Other languages
English (en)
Inventor
Carlo Farina
Stefania Gagliardi
Pietro A T Novella
Original Assignee
Claxosmithkline S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claxosmithkline S P A filed Critical Claxosmithkline S P A
Publication of ZA200200177B publication Critical patent/ZA200200177B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
ZA200200177A 1999-06-18 2002-01-09 Indole derivatives and their use for the treatment of osteoporosis amongst other applications. ZA200200177B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914371.1A GB9914371D0 (en) 1999-06-18 1999-06-18 Novel compounds

Publications (1)

Publication Number Publication Date
ZA200200177B true ZA200200177B (en) 2003-09-23

Family

ID=10855696

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200200177A ZA200200177B (en) 1999-06-18 2002-01-09 Indole derivatives and their use for the treatment of osteoporosis amongst other applications.

Country Status (30)

Country Link
US (2) US6787550B1 (cs)
EP (1) EP1212317B1 (cs)
JP (1) JP2003503490A (cs)
KR (1) KR100701109B1 (cs)
CN (1) CN1179960C (cs)
AR (1) AR024390A1 (cs)
AT (1) ATE276245T1 (cs)
AU (1) AU768726B2 (cs)
BR (1) BR0011708A (cs)
CA (1) CA2376657A1 (cs)
CO (1) CO5200757A1 (cs)
CZ (1) CZ301697B6 (cs)
DE (1) DE60013859T2 (cs)
DK (1) DK1212317T3 (cs)
ES (1) ES2226870T3 (cs)
GB (1) GB9914371D0 (cs)
GC (1) GC0000341A (cs)
HK (2) HK1049164A1 (cs)
HU (1) HUP0202049A3 (cs)
IL (2) IL147012A0 (cs)
MX (1) MXPA01013277A (cs)
MY (1) MY129425A (cs)
NO (1) NO322313B1 (cs)
NZ (1) NZ516131A (cs)
PL (1) PL352964A1 (cs)
PT (1) PT1212317E (cs)
TR (1) TR200103683T2 (cs)
TW (1) TWI248440B (cs)
WO (1) WO2001002388A1 (cs)
ZA (1) ZA200200177B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513092C (en) 2003-02-13 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
BRPI0412694A (pt) * 2003-07-15 2006-10-03 Smithkline Beecham Corp compostos
ITMI20040875A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici utili per il trattamento della resistenza agli agenti antitumorali
CA2583409C (en) 2004-09-17 2014-06-17 Idenix Pharmaceuticals, Inc. Phospho-indoles as hiv inhibitors
AU2005294404A1 (en) * 2004-10-04 2006-04-20 Myriad Genetics, Inc. Compounds for Alzheimer's disease
US7833805B2 (en) * 2004-10-21 2010-11-16 University Of Cincinnati Selectively permeable membranes on porous substrates
CN101233105B (zh) * 2005-07-20 2010-11-24 染井正德 色氨酸衍生物及其用途
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
BRPI0616994A2 (pt) * 2005-08-15 2011-07-05 Irm Llc compostos e composições como miméticos de tpo
EP1779848A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
US7915429B2 (en) 2006-01-25 2011-03-29 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7820721B2 (en) 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2639939A1 (en) 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009543805A (ja) * 2006-07-13 2009-12-10 スミスクライン ビーチャム コーポレーション インドリン誘導体及びｇｐｒ１１９作動物質
MX2009003410A (es) 2006-09-29 2009-07-17 Idenix Pharmaceuticals Inc Fosfoindoles enantiomericamente puros como inhibidores de vih.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
ES2806691T3 (es) 2009-02-16 2021-02-18 Nogra Pharma Ltd Compuestos de alquilamido y usos de los mismos
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
DK2614052T3 (en) * 2010-09-08 2015-04-07 Bristol Myers Squibb Co PIPERAZINE ANALYSIS UNKNOWN AS WIDE-SPECTIFIED ANTIVIRAL INFLUENZAMENTS
WO2012045451A1 (en) 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Novel therapeutic treatment of progranulin-dependent diseases
WO2012078416A2 (en) * 2010-12-06 2012-06-14 Rfs Pharma, Llc Monophosphate prodrugs of dapd and analogs thereof
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
HUE070120T2 (hu) 2019-02-08 2025-05-28 Nogra Pharma Ltd Eljárás 3-(4'-aminofenil)-2-metoxipropionsav és analógjai és intermedierei elõállítására
CN113024432A (zh) * 2019-12-24 2021-06-25 上海科胜药物研发有限公司 一种氨磺必利药典杂质的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
CZ217697A3 (cs) 1995-01-10 1998-03-18 Smithkline Beecham S. P. A. Indolové deriváty, kterých je možno použít pro léčení osteoporózy, způsob jejich přípravy, farmaceutický prostředek obsahující tyto deriváty a použití
PL330994A1 (en) 1996-07-09 1999-06-21 Smithkline Beecham Spa Indolic derivatives for use in treating osteoporosis
EP1042316B1 (en) * 1997-12-24 2005-02-09 Nikem Research S.R.L. Indole derivatives useful a.o. for the treatment of osteoporosis

Also Published As

Publication number Publication date
NZ516131A (en) 2003-10-31
CZ20014496A3 (cs) 2002-07-17
KR20020025079A (ko) 2002-04-03
KR100701109B1 (ko) 2007-03-29
HUP0202049A2 (hu) 2002-11-28
IL147012A0 (en) 2002-08-14
PL352964A1 (en) 2003-09-22
EP1212317A1 (en) 2002-06-12
AU5816500A (en) 2001-01-22
AR024390A1 (es) 2002-10-02
ES2226870T3 (es) 2005-04-01
DE60013859D1 (de) 2004-10-21
DK1212317T3 (da) 2005-01-24
TR200103683T2 (tr) 2003-01-21
MY129425A (en) 2007-03-30
HUP0202049A3 (en) 2003-12-29
CO5200757A1 (es) 2002-09-27
CN1370159A (zh) 2002-09-18
GC0000341A (en) 2007-03-31
JP2003503490A (ja) 2003-01-28
NO322313B1 (no) 2006-09-11
HK1049164A1 (zh) 2003-05-02
GB9914371D0 (en) 1999-08-18
CA2376657A1 (en) 2001-01-11
MXPA01013277A (es) 2002-06-04
CN1179960C (zh) 2004-12-15
WO2001002388A1 (en) 2001-01-11
NO20016149L (no) 2001-12-17
HK1048468B (en) 2005-07-29
ATE276245T1 (de) 2004-10-15
DE60013859T2 (de) 2005-09-29
BR0011708A (pt) 2002-05-21
PT1212317E (pt) 2005-02-28
US6787550B1 (en) 2004-09-07
US20040235930A1 (en) 2004-11-25
NO20016149D0 (no) 2001-12-17
CZ301697B6 (cs) 2010-05-26
HK1048468A1 (en) 2003-04-04
IL147012A (en) 2007-06-03
AU768726B2 (en) 2004-01-08
EP1212317B1 (en) 2004-09-15
TWI248440B (en) 2006-02-01

Similar Documents

Publication Publication Date Title
ZA200200177B (en) Indole derivatives and their use for the treatment of osteoporosis amongst other applications.
DE69527322T2 (de) 1H-Indol-3-Glyoxylamid sPLA2 Inhibitoren
US7220769B2 (en) Azolylbenzamides and analogues and their use for treating osteoporosis
JP2011148809A (ja) 抗腫瘍作用を有するインドリル−３−グリオキシル酸誘導体
JP6567505B2 (ja) キナゾリン誘導体およびｄｎａメチルトランスフェラーゼ阻害剤としてのその使用
TW200526219A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
RO105958B1 (ro) Procedeu pentru prepararea unor derivati de aminofenol
US6432987B2 (en) Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action
AU2003301853A1 (en) Indoles useful in the treatment of androgen- receptor related diseases
DD220308A5 (de) Verfahren zur herstellung von n(piperidinylalkyl)-carboxamiden
DE69021855T2 (de) Quinazolinderivate und ihre Herstellung.
JP4627881B2 (ja) 骨粗鬆症の治療に有用なａ．ｏ．インドール誘導体
US6506758B2 (en) Indole derivatives useful A.O. for the treatment of osteoporosis
JP2009067784A (ja) 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤
MXPA00006340A (en) Indole derivatives useful a.o. for the treatment of osteoporosis
HK1032953B (en) Indole derivatives useful a.o. for the treatment of osteoporosis
WO1991000275A1 (fr) Composes de butane ou leurs sels et leurs utilisations en medecine